TABLE 5.
Current Carrion's disease treatment schedules in Perua
| Demographic group | Phase | Illness | First-line treatment |
Second-line treatment |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antibiotic(s) | Dosec> | Interval | Duration | Route | Antibiotic(s) | Dosec | Interval (h) | Duration (days) | Route | ||||
| Childrenb | OF | Uncomplicated | AMC | 20 | 12 h | 14 days | p.o. | CIP | 5 | 12 | 14 | p.o. | |
| CHLd | 16.6/10 | 8 | 3/11 | p.o. | |||||||||
| SXT | 5 | 12 | 14 | p.o. | |||||||||
| Severe | CIP + CRO | CIP, 5–7.5 | 12 h | 14 days | i.v./p.o. | CIP + CAZ | CIP, 5–7.5 | 12 | 14 | i.v./p.o. | |||
| CRO, 70 | 24 he | 7–10 days | i.v. | CAZ, 16.6–33.3 | 8 | 7–10 | i.v. | ||||||
| CIP + AK | CIP, 5–7.5 | 12 | 14 | i.v./p.o. | |||||||||
| AK, 7.5 | 12 | 7–10 | i.v./i.m. | ||||||||||
| PW | AZM | 10 | 24 h | 7 days | p.o. | RFP | 10 | 24 | 21–28 | p.o. | |||
| ERY | 7.5–12.5 | 6 | 14 | p.o. | |||||||||
| CIP | 5 | 12 | 14 | p.o. | |||||||||
| Teenagers and adults | OF | Uncomplicated | CIP | 500 mg | 12 h | 14 days | p.o. | AMC | 1 g | 12 | 14 | p.o. | |
| SXT | 800 mg | 12 | 14 | p.o. | |||||||||
| CHLd | 16.6/10 | 8 | 3/11 | p.o. | |||||||||
| Severe | CIP + CRO | CIPf, 400/200 mg | 12 h | 3 days/11 days | i.v./p.o. | CIP + CAZ | CIPf, 400/200 mg | 12 | 3/11 | i.v./p.o. | |||
| CRO, 2 g | 24 h | 7–10 days | i.v. | CAZ, 1 g | 8 | 7 | i.v. | ||||||
| CIP+AK | CIPf, 400/200 mg | 12 | 3/11 | i.v./p.o. | |||||||||
| AKg, 7.5 | 12 | 7–10 | i.v./i.m. | ||||||||||
| PW | AZM | 500 mg | 24 h | 7 days | p.o. | RIF | 600 mg | 24 | 21–28 | p.o. | |||
| ERY | 500 mg | 6 | 14 | p.o. | |||||||||
| CIP | 500 mg | 12 | 14 | p.o. | |||||||||
| Pregnant or breast-feeding women | OF | Uncomplicated | AMC | 1 g | 12 h | 14 days | p.o. | CHLd | 16.6/10 | 8 | 3/11 | p.o. | |
| SXT | 800 mg | 12 | 14 | p.o. | |||||||||
| AMX | 1 g | 8 | 14 | p.o. | |||||||||
| Severe | CRO + CHL | CRO | 1 g | 12 h | 10 days | i.v. | CRO + AK | CRO, 1 g | 12 | 10 | i.v. | ||
| AK, 500 mg | 12 | 7–10 | i.v./i.m. | ||||||||||
| CHLh | 1 g/500 mg | 8 h/6 h | 5 days/11 days | i.v./p.o. | CAZ + AK | CAZ, 1 g | 12 | 10 | i.v. | ||||
| AK, 500 mg | 12 | 7–10 | i.v./i.m. | ||||||||||
| PW | AZM | 1 g | 1 day/1 wki | 3 w | RFP | 600 mg | 24 | 21–28 | p.o. | ||||
| ERY | 500 mg | 6 | 14 | p.o. | |||||||||
Based on current official guidelines (34, 377). Abbreviations: OF, Oroya fever; PW, Peruvian warts; p.o., oral; i.v., intravenous; i.m., intramuscular; AK, amikacin; AMC, amoxicillin plus clavulanic acid; AMX, amoxicillin; AZM, azithromycin; CAZ, ceftazidime; CIP, ciprofloxacin; CRO, ceftriaxone; CHL, chloramphenicol; ERY, erythromycin; RFP, rifampin; SXT, co-trimoxazole.
Individuals up to 14 years old or weighing <45 kg (if the weight is higher the teenager/adult guidelines will be followed). Doses for children are reported in milligrams per kilogram of body weight. Note that specific situations or complications may require schedule modifications (34, 377). In addition, for adults/teenagers and for pregnant women when no units are indicated, the doses are reported in milligrams per kilogram of body weight.
For amoxicillin plus clavulanic acid or co-trimoxazole, the dose is in reference to the first antibiotic compound of each combination.
Fifty milligrams per kilogram per day for 3 days; thereafter, 30 mg/kg/day for 11 days.
In the guidelines 70 mg/kg/day is indicated, but no dosage information is provided.
Four hundred milligrams every 12 h for 3 days; thereafter, 200 mg every 12 h.
The maximum dose is 1.5 g/day.
One gram every 8 h for 5 days (i.v.) followed by 500 mg every 6 h for 11 days (p.o., if possible).
One gram per day once a week for 3 weeks.